查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726328

美國生物製藥契約製造市場：市場規模、佔有率、趨勢分析（按原料、服務、產品、類型、業務規模和治療領域）、細分市場預測（2025-2030 年）

U.S. Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trends Analysis Report By Source, By Service, By Products, By Type, By Scale Of Operation, By Therapeutic Area, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國生物製藥契約製造市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，美國生物製藥契約製造市場預計到 2030 年將達到 195.4 億美元，2025 年至 2030 年期間的複合年成長率為 10.6%。

由於對採用創新治療方法複雜疾病的生技藥品和生物相似藥的需求不斷增加，美國生物製藥契約製造市場正在成長。一次性系統和連續加工等製造技術的進步正在提高生產效率和擴充性。這些因素使契約製造製造商能夠滿足對具有成本效益的高品質生物製藥日益成長的需求，從而推動市場成長並激發行業創新。

由於注重成本效益生產和合約製造業務(CMO) 的擴張，市場正在蓬勃發展。外包製造可以讓公司降低營運成本並將資源分配到創新上。 CMO 提供可擴展的解決方案、先進的技術和專業知識，以確保高效生產。 CMO 的成長將使生物製藥公司能夠滿足對生技藥品和生物相似藥日益成長的需求，促進市場擴張並激發行業創新。

慢性病的增加推動了對先進生物藥物（包括生技藥品和生物相似藥）的需求，以應對複雜的健康挑戰。同時，一次性系統和連續生產等生物加工領域的創新正在徹底改變生產效率和可擴展性。這些進步使契約製造製造商能夠滿足對高品質、具成本效益治療方法日益成長的需求，為美國生物製藥行業的成長和發展做出了重大貢獻。

美國生物製藥契約製造市場：概述

  • 基於原料，哺乳動物部分在製造單株抗體和重組蛋白等生技藥品方面發揮著至關重要的作用，預計到 2024 年將佔據最大佔有率。
  • 按服務分類，流程開發部門在 2024 年佔據市場最大收入佔有率，達 34.8%。這是因為它在最佳化生產效率和確保法規遵循方面發揮著至關重要的作用。
  • 由於生物製藥製造對嚴格品質保證和法規遵從性的需求日益增加，預計分析和品管(QC) 研究領域在預測期內將以最快的複合年成長率成長。
  • 根據產品，由於對單株抗體、細胞和基因療法以及生物相似藥等先進療法的需求不斷增加，生技藥品領域預計將在 2024 年佔據最大佔有率。
  • 預計生物相似藥領域將成為 2025 年至 2030 年間成長最快的領域。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章美國生物製藥契約製造市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL分析

第4章美國生物製藥契約製造市場：原料業務分析

  • 原料市場佔有率（2024 年及 2030 年）
  • 按成分分類的儀表板
  • 按原料分類的市場規模預測與趨勢分析（2018-2030）
  • 哺乳動物
  • 非哺乳動物

第5章美國生物製藥契約製造市場：按服務分類的業務分析

  • 各服務市場佔有率（2024 年及 2030 年）
  • 特定於服務的儀表板
  • 市場規模預測及服務趨勢分析（2018-2030）
  • 製程開發
  • 填充和整理工作
  • 分析和品管（QC）調查
  • 包裝和標籤
  • 其他

第6章美國生物製藥契約製造市場：按產品分類的業務分析

  • 各產品市場佔有率（2024 年及 2030 年）
  • 產品儀表板
  • 市場規模預測及產品趨勢分析（2018-2030）
  • 生技藥品
  • 生物相似藥

第7章美國生物製藥契約製造市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2024 年和 2030 年）
  • 按類型分類的儀表板
  • 按類型分類的市場規模預測和趨勢分析（2018-2030）
  • 原料藥
  • 成品藥品

第8章美國生物製藥契約製造市場：按業務規模進行的業務分析

  • 按企業規模分類的市場佔有率（2024 年和 2030 年）
  • 按業務規模分類的儀表板
  • 按業務規模分類的市場規模預測和趨勢分析（2018-2030 年）
  • 臨床
  • 實際的

第9章美國生物製藥契約製造市場：按治療領域分類的業務分析

  • 按治療領域分類的市場佔有率（2024 年和 2030 年）
  • 治療區域儀表板
  • 依治療領域分類的市場規模預測及趨勢分析（2018-2030）
  • 瘤
  • 自體免疫疾病
  • 感染疾病
  • 心血管疾病
  • 代謝疾病
  • 神經病學
  • 其他

第10章 競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Lonza
    • WuXi Biologics
    • FUJIFILM Diosynth Biotechnologies
    • Boehringer Ingelheim International GmbH
    • Thermo Fisher Scientific Inc.
    • Samsung Biologics
    • AGC Biologics
    • Catalent, Inc
    • Rentschler Biopharma SE
    • Eurofins Scientific
Product Code: GVR-4-68040-223-7

U.S. Biopharmaceuticals Contract Manufacturing Market Growth & Trends:

The U.S. biopharmaceuticals contract manufacturing market is anticipated to reach USD 19.54 billion by 2030 and expand at a CAGR of 10.6% from 2025 to 2030, according to a new report by Grand View Research, Inc.The U.S. biopharmaceuticals contract manufacturing market is growing due to the rising demand for biologics and biosimilars, which address complex diseases with innovative therapies. Advancements in manufacturing technologies, such as single-use systems and continuous processing, enhance production efficiency and scalability. These factors enable contract manufacturers to meet the rising need for cost-effective and high-quality biopharmaceuticals, driving market growth and fostering innovation in the industry.

The market thrives due to a focus on cost-effective production and the expansion of Contract Manufacturing Organizations (CMOs). By outsourcing manufacturing, companies reduce operational costs and allocate resources for innovation. CMOs provide scalable solutions, advanced technologies, and specialized expertise, ensuring efficient production. Their growth enables biopharma companies to meet the rising demand for biologics and biosimilars, driving market expansion and fostering innovation in industry.

The growing prevalence of chronic diseases fuels the demand for advanced biopharmaceuticals, including biologics and biosimilars, to address complex health challenges. Simultaneously, technological innovations in bioprocessing, such as single-use systems and continuous manufacturing, are revolutionizing production efficiency and scalability. These advancements empower contract manufacturers to meet the rising need for high-quality, cost-effective therapies and contribute significantly to the growth and evolution of the biopharmaceutical industry in the U.S.

U.S. Biopharmaceuticals Contract Manufacturing Market Report Highlights:

  • By source, the mammalian segment held the largest share in 2024, owing toits critical role in producing biologics like monoclonal antibodies and recombinant proteins.
  • By service, the process development segment led the market with the largest revenue share of 34.8% in 2024, driven byits pivotal role in optimizing production efficiency and ensuring regulatory compliance.
  • Theanalytical & QC studies segment is set to grow at the fastest CAGR over the forecast period, fueled bythe increasing need for stringent quality assurance and regulatory compliance in biopharmaceutical production.
  • By products, the biologics segment dominated the market with the largest share in 2024 due toincreasing demand for advanced therapies like monoclonal antibodies, cell and gene therapies, and biosimilars.
  • The biosimilars segment is projected to be the fastest-growing segment from 2025 to 2030, attributed to increasing demand for cost-effective alternatives to biologics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Source
    • 1.2.2. Service
    • 1.2.3. Products
    • 1.2.4. Type
    • 1.2.5. Scale of Operation
    • 1.2.6. Therapeutic Area
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Biopharmaceuticals Contract Manufacturing Market: Source Business Analysis

  • 4.1. Source Market Share, 2024 & 2030
  • 4.2. Source Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Source, 2018 to 2030 (USD Million)
  • 4.4. Mammalian
    • 4.4.1. Mammalian Market, 2018 - 2030 (USD Million)
  • 4.5. Non-mammalian
    • 4.5.1. Non-mammalian Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Biopharmaceuticals Contract Manufacturing Market: Service Business Analysis

  • 5.1. Service Market Share, 2024 & 2030
  • 5.2. Service Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process Development Market, 2018 - 2030 (USD Million)
    • 5.4.2. Downstream
      • 5.4.2.1. Downstream Market, 2018 - 2030 (USD Million)
    • 5.4.3. Upstream
      • 5.4.3.1. Upstream Market, 2018 - 2030 (USD Million)
  • 5.5. Fill & Finish Operations
    • 5.5.1. Fill & Finish Operations Market, 2018 - 2030 (USD Million)
  • 5.6. Analytical & QC Studies
    • 5.6.1. Analytical & QC Studies Market, 2018 - 2030 (USD Million)
  • 5.7. Packaging & Labelling
    • 5.7.1. Packaging & Labelling Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Biopharmaceuticals Contract Manufacturing Market: Products Business Analysis

  • 6.1. Products Market Share, 2024 & 2030
  • 6.2. Products Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, By Products, 2018 to 2030 (USD Million)
  • 6.4. Biologics
    • 6.4.1. Biologics Market, 2018 - 2030 (USD Million)
    • 6.4.2. Monoclonal Antibodies (mAbs)
      • 6.4.2.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
    • 6.4.3. Recombinant Proteins
      • 6.4.3.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
    • 6.4.4. Vaccines
      • 6.4.4.1. Vaccines Market, 2018 - 2030 (USD Million)
    • 6.4.5. Antisense, RNAi, & Molecular Therapy
      • 6.4.5.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Biosimilars
    • 6.5.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Biopharmaceuticals Contract Manufacturing Market: Type Business Analysis

  • 7.1. Type Market Share, 2024 & 2030
  • 7.2. Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, By Type, 2018 to 2030 (USD Million)
  • 7.4. Drug Substance
    • 7.4.1. Drug Substance Market, 2018 - 2030 (USD Million)
  • 7.5. Finished Drug Product
    • 7.5.1. Finished Drug Product Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Business Analysis

  • 8.1. Scale of Operation Market Share, 2024 & 2030
  • 8.2. Scale of Operation Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, By Scale of Operation, 2018 to 2030 (USD Million)
  • 8.4. Clinical
    • 8.4.1. Clinical Market, 2018 - 2030 (USD Million)
  • 8.5. Commercial
    • 8.5.1. Commercial Market, 2018 - 2030 (USD Million)

Chapter 9. U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Business Analysis

  • 9.1. Therapeutic Area Market Share, 2024 & 2030
  • 9.2. Therapeutic Area Segment Dashboard
  • 9.3. Market Size & Forecasts and Trend Analysis, By Therapeutic Area, 2018 to 2030 (USD Million)
  • 9.4. Oncology
    • 9.4.1. Oncology Market, 2018 - 2030 (USD Million)
  • 9.5. Autoimmune Diseases
    • 9.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
  • 9.6. Infectious Diseases
    • 9.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 9.7. Cardiovascular Diseases
    • 9.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 9.8. Metabolic Diseases
    • 9.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
  • 9.9. Neurology
    • 9.9.1. Neurology Market, 2018 - 2030 (USD Million)
  • 9.10. Others
    • 9.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Lonza
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. WuXi Biologics
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. FUJIFILM Diosynth Biotechnologies
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Boehringer Ingelheim International GmbH
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Thermo Fisher Scientific Inc.
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Samsung Biologics
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. AGC Biologics
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Product Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. Catalent, Inc
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Product Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Rentschler Biopharma SE
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Product Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. Eurofins Scientific
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Biopharmaceuticals Contract Manufacturing Market, By Source, 2018 - 2030 (USD Million)
  • Table 4 U.S. Biopharmaceuticals Contract Manufacturing Market, By Service, 2018 - 2030 (USD Million)
  • Table 5 U.S. Biopharmaceuticals Contract Manufacturing Market, By Products, 2018 - 2030 (USD Million)
  • Table 6 U.S. Biopharmaceuticals Contract Manufacturing Market, By Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Biopharmaceuticals Contract Manufacturing Market, By Scale of Operation, 2018 - 2030 (USD Million)
  • Table 8 U.S. Biopharmaceuticals Contract Manufacturing Market, By Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. Biopharmaceuticals Contract Manufacturing Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Service and Technique Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 U.S. Biopharmaceuticals Contract Manufacturing Market Dynamics
  • Fig. 12 U.S. Biopharmaceuticals Contract Manufacturing Market: Porter's Five Forces analysis
  • Fig. 13 U.S. Biopharmaceuticals Contract Manufacturing Market: PESTLE Analysis
  • Fig. 14 U.S. Biopharmaceuticals Contract Manufacturing Market: Source Segment Dashboard
  • Fig. 15 U.S. Biopharmaceuticals Contract Manufacturing Market: Source Market Share Analysis, 2024 & 2030
  • Fig. 16 Mammalian Market, 2018 - 2030 (USD Million)
  • Fig. 17 Mammalian Market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Biopharmaceuticals Contract Manufacturing Market: Service Segment Dashboard
  • Fig. 19 U.S. Biopharmaceuticals Contract Manufacturing Market: Service Market Share Analysis, 2024 & 2030
  • Fig. 20 Process Development Market, 2018 - 2030 (USD Million)
  • Fig. 21 Downstream Market, 2018 - 2030 (USD Million)
  • Fig. 22 Upstream Market, 2018 - 2030 (USD Million)
  • Fig. 23 Fill & Finish Operations Market, 2018 - 2030 (USD Million)
  • Fig. 24 Analytical & QC Studies Market, 2018 - 2030 (USD Million)
  • Fig. 25 Packaging & Labelling Market, 2018 - 2030 (USD Million)
  • Fig. 26 Others Market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Biopharmaceuticals Contract Manufacturing Market: Products Segment Dashboard
  • Fig. 28 U.S. Biopharmaceuticals Contract Manufacturing Market: Products Market Share Analysis, 2024 & 2030
  • Fig. 29 Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 30 Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
  • Fig. 31 Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 32 Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 33 Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 34 Others Market, 2018 - 2030 (USD Million)
  • Fig. 35 Biosimilars Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Biopharmaceuticals Contract Manufacturing Market: Type Segment Dashboard
  • Fig. 37 U.S. Biopharmaceuticals Contract Manufacturing Market: Type Market Share Analysis, 2024 & 2030
  • Fig. 38 Drug Substance Market, 2018 - 2030 (USD Million)
  • Fig. 39 Finished Drug Product Market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Segment Dashboard
  • Fig. 41 U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Market Share Analysis, 2024 & 2030
  • Fig. 42 Clinical Market, 2018 - 2030 (USD Million)
  • Fig. 43 Commercial Market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Segment Dashboard
  • Fig. 45 U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Market Share Analysis, 2024 & 2030
  • Fig. 46 Oncology Market, 2018 - 2030 (USD Million)
  • Fig. 47 Autoimmune Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 48 Infectious Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 49 Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 50 Metabolic Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 51 Neurology Market, 2018 - 2030 (USD Million)
  • Fig. 52 Others Market, 2018 - 2030 (USD Million)
  • Fig. 53 Company Categorization
  • Fig. 54 Company Market Position Analysis
  • Fig. 55 Strategic Framework